PMID- 12148364
OWN - NLM
STAT- MEDLINE
DCOM- 20020821
LR  - 20220309
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 31
IP  - 17
DP  - 2002 May 11
TI  - [Neo-adjuvant chemotherapy of non-small cell bronchial cancers (NSCLC)].
PG  - 797-801
AB  - TO PROLONG SURVIVAL: Systemic neo-adjuvant chemotherapy attempts to reduce the 
      development of metastases. Data available on neoadjuvant chemotherapy of NSCLC 
      come from three types of clinical trials. NEO-ADJUVANT CHEMOTHERAPY PHASE II 
      TRIALS: Many trials have demonstrated that the neo-adjuvant approach is feasible, 
      that it leads to a high rate of response, to the order of 50 to 70%, that it does 
      not compromise surgery, and exhibits acceptable toxicity. High survival rates 
      have been obtained, notably in total responders. NEO-ADJUVANT CHEMO-RADIOTHERAPY 
      PHASE II TRIALS: Have essentially demonstrated that this approach is feasible, 
      exhibits acceptable toxicity, worse in pneumonectomy. High response rates have 
      been obtained and relative improved survival, since most of the cases concerned 
      extensive forms that could not be treated surgically. RANDOMIZED PHASE III 
      TRIALS: Gave varying results: two of them only concerned small series of patients 
      (60 in all) with stage IIIA NSCB, with positive results. The third study 
      concerned 373 patients with stage I, II and IIIA cancers: survival at 3 years was 
      increased by 11%, but this difference is not yet significant. Benefits were 
      essentially apparent for stage I and II patients. IN THE FUTURE: Continued active 
      clinical research, oriented differently, on stage I and II, and stage IIIA is 
      necessary.
FAU - Milleron, Bernard
AU  - Milleron B
AD  - Service de pneumologie, Hopital Tenon, 4, rue de la Chine, 75020 Paris.
FAU - Westeel, Virginie
AU  - Westeel V
FAU - Depierre, Alain
AU  - Depierre A
LA  - fre
PT  - Journal Article
PT  - Review
TT  - La chimiotherapie neo-adjuvante des cancers bronchiques non a petites cellules 
      (CBNPC).
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/radiotherapy/surgery
MH  - *Chemotherapy, Adjuvant/adverse effects
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Humans
MH  - Lung Neoplasms/diagnostic imaging/*drug therapy/pathology/surgery
MH  - *Neoadjuvant Therapy/adverse effects
MH  - Neoplasm Metastasis/prevention & control
MH  - Radiography
RF  - 40
EDAT- 2002/08/01 10:00
MHDA- 2002/08/22 10:01
CRDT- 2002/08/01 10:00
PHST- 2002/08/01 10:00 [pubmed]
PHST- 2002/08/22 10:01 [medline]
PHST- 2002/08/01 10:00 [entrez]
PST - ppublish
SO  - Presse Med. 2002 May 11;31(17):797-801.